Compare COLL & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COLL | PGY |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | 518 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 971.3M |
| IPO Year | 2015 | N/A |
| Metric | COLL | PGY |
|---|---|---|
| Price | $33.62 | $13.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $51.40 | $34.50 |
| AVG Volume (30 Days) | 428.8K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $8.01 | $14.27 |
| Revenue Next Year | N/A | $14.39 |
| P/E Ratio | $87.03 | ★ $13.54 |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $28.34 | $10.40 |
| 52 Week High | $50.79 | $44.99 |
| Indicator | COLL | PGY |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 48.21 |
| Support Level | $31.56 | $10.78 |
| Resistance Level | $36.22 | $15.57 |
| Average True Range (ATR) | 1.70 | 0.85 |
| MACD | 0.00 | -0.17 |
| Stochastic Oscillator | 16.17 | 18.60 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.